Park Hanjin, Norby Faye L, Kim Daehoon, Jang Eunsun, Yu Hee Tae, Kim Tae-Hoon, Uhm Jae-Sun, Sung Jung-Hoon, Pak Hui-Nam, Lee Moon-Hyoung, Yang Pil-Sung, Joung Boyoung
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea (H.P., D.K., E.J., H.T.Y., T.-H.K., J.-S.U., H.-N.P., M.-H.L., B.J.).
Division of Epidemiology and Community Health, University of Minnesota, School of Public Health, Minneapolis (F.L.N.).
Circulation. 2025 Jul 29;152(4):217-229. doi: 10.1161/CIRCULATIONAHA.124.073457. Epub 2025 May 22.
Proteomic signatures might improve disease prediction and enable targeted disease prevention and management. We explored whether a protein risk score derived from large-scale proteomics data improves risk prediction of atrial fibrillation (AF).
A total of 51 680 individuals with 1459 unique plasma protein measurements and without a history of AF were included from the UKB-PPP (UK Biobank Pharma Proteomics Project). A protein risk score was developed with lasso-penalized Cox regression from a random subset of 70% (36 176 individuals, 54.4% women, 2155 events) and was tested on the remaining 30% (15 504 individuals, 54.4% women, 910 events). The protein risk score was externally replicated with the ARIC study (Atherosclerosis Risk in Communities; 11 012 individuals, 54.8% women, 1260 events).
The protein risk score formula developed from the UKB-PPP derivation set was composed of 165 unique plasma proteins, and 15 of them were associated with atrial remodeling. In the UKB-PPP test set, a 1-SD increase in protein risk score was associated with a hazard ratio of 2.20 (95% CI, 2.05-2.41) for incident AF. The C index for a model including CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology Atrial Fibrillation), NT-proBNP (N-terminal B-type natriuretic peptide), polygenic risk score, and protein risk score was 0.816 (95% CI, 0.802-0.829) compared with 0.771 (95% CI, 0.755-0.787) for a model including CHARGE-AF, NT-proBNP, and polygenic risk score (C-index change, 0.044 [95% CI, 0.039-0.055]). Protein risk score added to CHARGE-AF, NT-proBNP, and polygenic risk score resulted in a risk reclassification of 5.4% (95% CI, 2.9%-7.9%) with a 5-year risk threshold of 5%. In the decision curve, the predicted net benefit before and after the addition of protein risk score to a model including CHARGE-AF, NT-proBNP, and polygenic risk score was 3.8 and 5.4 per 1000 people, respectively, at a 5-year risk threshold of 5%. External replication of a protein risk score in the ARIC study showed consistent improvement in risk stratification of AF.
Protein risk score derived from a single plasma sample improved risk prediction of AF. Further research using proteomic signatures in AF screening and prevention is needed.
蛋白质组学特征可能会改善疾病预测,并实现针对性的疾病预防和管理。我们探讨了从大规模蛋白质组学数据得出的蛋白质风险评分是否能改善房颤(AF)的风险预测。
从UKB-PPP(英国生物银行药物蛋白质组学项目)纳入了51680名个体,他们有1459种独特的血浆蛋白测量值且无房颤病史。通过套索惩罚Cox回归从70%的随机子集中(36176名个体,54.4%为女性,2155例事件)开发了一个蛋白质风险评分,并在其余30%(15504名个体,54.4%为女性,910例事件)上进行测试。该蛋白质风险评分在ARIC研究(社区动脉粥样硬化风险研究;11012名个体,54.8%为女性,1260例事件)中进行了外部验证。
从UKB-PPP推导集开发的蛋白质风险评分公式由165种独特的血浆蛋白组成,其中15种与心房重构相关。在UKB-PPP测试集中,蛋白质风险评分增加1个标准差与新发房颤的风险比为2.20(95%CI,2.05-2.41)相关。包含CHARGE-AF(基因组流行病学心脏与衰老研究队列房颤)、NT-proBNP(N末端B型利钠肽原)、多基因风险评分和蛋白质风险评分的模型的C指数为0.816(95%CI,0.802-0.829),而包含CHARGE-AF、NT-proBNP和多基因风险评分的模型的C指数为0.771(95%CI,0.755-0.787)(C指数变化,0.044[95%CI,0.039-0.055])。将蛋白质风险评分添加到CHARGE-AF、NT-proBNP和多基因风险评分中,导致5.4%(95%CI,2.9%-7.9%)的风险重新分类,5年风险阈值为5%。在决策曲线中,在5年风险阈值为5%时,将蛋白质风险评分添加到包含CHARGE-AF、NT-proBNP和多基因风险评分的模型前后,预测的每1000人净效益分别为3.8和5.4。ARIC研究中蛋白质风险评分的外部验证显示房颤风险分层有一致的改善。
从单个血浆样本得出的蛋白质风险评分改善了房颤的风险预测。需要在房颤筛查和预防中使用蛋白质组学特征进行进一步研究。